[Choice of anti-helicobacter treatment of gastroduodenal ulcer associated with helicobater pylori].
OBJECTIVE
Choice of optimal antihelicobacter (AH) treatment of ulcer.


METHODS
249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin.


RESULTS
Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective.


CONCLUSIONS
Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.
Starostin
B D
BD
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D007413:Intestinal Mucosa / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents